| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8454004 | Lung Cancer | 2018 | 6 Pages |
Abstract
The T790M ratio to EGFR activating mutation in tumor may correlate with the response to osimertinib, and patients with a higher T790M ratio have a longer treatment history.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Ryo Ariyasu, Shingo Nishikawa, Ken Uchibori, Tomoko Oh-hara, Takahiro Yoshizawa, Yosuke Dotsu, Junji Koyama, Masafumi Saiki, Tomoaki Sonoda, Satoru Kitazono, Noriko Yanagitani, Atsushi Horiike, Naohiko Inase, Kazuo Kasahara, Makoto Nishio,